| **Title** | Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: Vaccinia Tiantan strain |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Author(s)** | Chen, Z; Lu, B; Yu, W; Huang, X; Wang, H; Liu, L |
| **Citation** | Journal Of Biomedicine And Biotechnology, 2011, v. 2011 |
| **Issued Date** | 2011 |
| **URL** | http://hdl.handle.net/10722/137593 |
| **Rights** | Creative Commons: Attribution 3.0 Hong Kong License |
Research Article

Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain

Bin Lu,1 Wenbo Yu,2 Xiaoxing Huang,1 Haibo Wang,2 Li Liu,2 and Zhiwei Chen2,3

1 AIDS Center and Modern Virology Research Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei 430072, China
2 AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
3 Department of Microbiology and Research Center for Infection and Immunity, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong

Correspondence should be addressed to Zhiwei Chen, zchenai@hku.hk

Received 23 February 2011; Revised 18 April 2011; Accepted 19 April 2011

Academic Editor: Young-Chul Sung

Copyright © 2011 Bin Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The possible bioterrorism threat using the variola virus, the causative agent of smallpox, has promoted us to further investigate the immunogenicity profiles of existing vaccines. Here, we study for the first time the immunogenicity profile of a replication-competent smallpox vaccine (vaccinia Tiantan, VTT strain) for inducing neutralizing antibodies (Nabs) through mucosal vaccination, which is noninvasive and has a critical implication for massive vaccination programs. Four different routes of vaccination were tested in parallel including intramuscular (i.m.), intranasal (i.n.), oral (i.o.), and subcutaneous (s.c.) inoculations in mice. We found that one time vaccination with an optimal dose of VTT was able to induce anti-VTT Nabs via each of the four routes. Higher levels of antiviral Nabs, however, were induced via the i.n. and i.o. inoculations when compared with the i.m. and s.c. routes. Moreover, the i.n. and i.o. vaccinations also induced higher sustained levels of Nabs overtime, which conferred better protections against homologous or alternating mucosal routes of viral challenges six months post vaccination. The VTT-induced immunity via all four routes, however, was partially effective against the intramuscular viral challenge. Our data have implications for understanding the potential application of mucosal smallpox vaccination and for developing VTT-based vaccines to overcome preexisting antivaccinia immunity.

1. Introduction

Smallpox, which was caused by infection with the variola virus, was one of the most deadly diseases in human history with a mortality rate of up to 50% [1, 2]. Fortunately, this disease was completely eradicated throughout the world by 1980 after the introduction of a global smallpox vaccination campaign [3]. During this process, vaccinia virus, which shares broad antigenic properties with the variola virus, played an essential role as an effective vaccine in inducing protective immunity against smallpox [3–5]. It is well accepted that vaccine-induced neutralizing antibodies are critical to protection [6–8]. The fear of variola virus being deliberately released in potential bioterrorism attacks and the increasing use of vaccinia as vaccine vectors for other diseases such as AIDS have led to more recent studies aimed at understanding the protective immune responses induced by the smallpox vaccine [9, 10]. It is, therefore, necessary to investigate the neutralizing antibody responses induced by historically used smallpox vaccines via different route of vaccination.

The most extensively used smallpox vaccine in China was the vaccinia virus Tiantan (VTT) strain [11]. Accordingly, the original VTT was isolated from the skin lesion of a smallpox patient in China around 1926 followed by extensive passages of 3 times in monkeys, 5 in rabbits, 3 in bovines,
then twice in rabbits and 3 times in bovines, repeatedly [12, 13]. Genetic analysis of VTT genome, however, suggested that it is a vaccinia strain instead of a variola viral variant [14]. The clinical safety of this vaccine has not been clearly documented although VTT was historically used for millions of people. These issues are essential for a safe smallpox vaccine [15]. The biological characteristics of VTT have been described in our recent studies [16, 17]. It was reported that VTT caused larger lesions after intradermal vaccination and was likely more virulent than other widely used smallpox vaccines such as Lister or Wyeth [12, 18]. To date, whether or not VTT can induce protective neutralizing antibody responses through noninvasive mucosal vaccination remains less understood [19, 20].

Here, we study VTT to investigate its immunogenicity in terms of inducing neutralizing antibodies through four different routes of vaccination in a mouse model, which has not been previously studied. Moreover, by conducting homologous and heterologous routes of viral challenges, we aimed to determine the efficacy of VTT for protection and to identify a strategy to overcome preexisting immunity to VTT-based vaccines. This study involved a safe, nonpathogenic viral challenge model using a high dose of modified VTT, namely, MVTT-S, which expresses the spike (S) glycoprotein of SARS-CoV. Since S is not expressed on the surface of vaccinia virus, we aimed to determine the role of anti-VTT neutralizing antibody (Nab) responses in achieving protection by evaluating the seroconversion to S. Our results have implications for understanding an aspect of vaccinia-induced protective immunity and for developing vaccinia-based vaccines.

2. Materials and Methods

2.1. Virus Stock and Cell Line. The background and biological properties of the smallpox vaccine vaccinia TianTan (VTT) have been described previously [16]. VTT stocks were propagated in Vero cells and then purified by repeated freezing and thawing and centrifugation through a 36% sucrose cushion. The viral pellet was subjected to a sucrose gradient centrifugation. Purified viruses were collected and studied [21]. The plaque forming unit (PFU) of viral stocks was titrated on Vero cells by a plaque-forming assay using crystal violet staining. The construction and characterization of the challenge virus MVTT-S have been described previously [17].

2.2. Immunization of Mice. Five groups of female BALB/c mice were included in the study. Each group of nine mice was inoculated with an optimal dose of 10⁶ PFU VTT through one of four different routes including intramuscular (i.m.), intranasal (i.n.), oral (i.o.), and subcutaneous (s.c.) inoculations, respectively, [17]. Another group of nine mice received a placebo as controls. To measure lasting Nab responses, mice were kept for six months for observation and testing.

2.3. Viral Challenge of VTT-Immunized Mice. After six months of observation, each group of mice was further divided into three subgroups. Each subgroup of three mice was challenged with a dose of 2 × 10⁶ PFU MVTT-S through one of three different routes including i.m., i.n., and i.o., respectively. It is the highest dose possible for mucosal challenge based on the concentration of our viral stocks and the size of animals. After a three-week interval, all animals were challenged again with the same dose of 2 × 10⁶ PFU MVTT-S. Blood samples were collected on week 3, week 26, week 29, and week 32 for measuring Nab responses after MVTT-S challenge. Our animal protocols were approved by the Institutional Committee on Laboratory Animal Use of Wuhan University. Since MVTT-S is an attenuated VTT variant which is not lethal in mice, we define the full protection by the lack of detectable anti-S Nab response induced by the challenge virus MVTT-S in this study.

2.4. Anti-S Neutralizing Assay. A pseudovirus-based neutralization assay was applied to determine the humoral immune responses against the S glycoprotein of SARS-CoV [22]. The pseudotype virus was generated by cotransfecting 293T cells with two plasmids pcDNA-Sopt9 and pNL4-3Luc+Env–Vpr– carrying the optimized S gene and a human immunodeficiency virus type 1 backbone, respectively. For each experiment, pooled sera, which contain an equal amount of serum of each vaccinated mouse in each group, were subjected to the assay as described by others [23]. Luciferase activity was measured by the PerkinElmer Victor Microplate Reader according to manufacturer’s instruction. In comparison to serum samples of unvaccinated mice in the same experiments, we score seropositive when an IC₅₀ value reaches a serum dilution factor of 1 : 30. An IC₅₀ value is a serum dilution factor that achieves 50% of viral inhibition.

2.5. Anti-VTT Neutralizing Assay. To test the serum neutralization activity against VTT, we used a flow-cytometry-based assay similar to a previously published method [24]. For this assay, a modified VTT that contains a GFP (MVTT-GFP) expression cassette was constructed [14]. Briefly, the neutralizing activity of heat-inactivated sera (56°C, 30 min) was determined by mixing 1.25 × 10⁶ PFU/mL of VTT-GFP virus in 20 μL with an equal amount of diluted serum at 37°C for 1 h. After the incubation, 60 μL of the 293T cells were added into each well of the plate and incubated at 37°C. 293T cells were diluted into 2.5 × 10⁵/mL using culture medium containing 10% FBS, 1% streptomycin and penicillin, and 44 μg of cytosine arabinoside per mL. After 24 hr incubation, the infected cells were washed with PBS twice and then trypsinized (50 μL/well trypsin). The cells were pelleted, washed, and then fixed with 200 μL of 2% paraformaldehyde, and subsequently subjected to the FACS analysis. The titer of viral neutralization was determined by calculating the percent reduction of infected cells showing GFP positive expression. Similarly, an IC₅₀ value is a serum dilution factor that achieves 50% of viral inhibition.
2.6. Statistical Analyses. The Student's t-test was used to evaluate the statistical significance of Nab titers among various groups of animals. The Origin 8 computer software was used for this analysis.

3. Results

3.1. Higher Levels of Anti-VTT Nabs Were Induced via the i.n. and i.o. Inoculations When Compared with the i.m. and s.c. Routes. In this study, we sought to determine whether VTT would induce different levels of Nabs via various routes of vaccination. This is a critical question because VTT was historically used as a smallpox vaccine for millions of people yet its potential use as a noninvasive vaccine remains elusive. To address this question, four groups of mice were inoculated with an optimal dose of 10⁶ PFU VTT via s.c., i.m., i.n., and i.o. routes, respectively. Another group of mice received a placebo as controls. Three weeks after inoculation, the animals were tested for the production of anti-VTT Nabs using a newly developed FACs-based MVTT-GFP neutralization assay (Figure 1(a)) [24]. Since the sample quantity is small, pooled sera were tested for each experimental group. The pooled sera contain an equal amount of serum of individual mice in each group. We found that each route of vaccination was able to induce anti-VTT Nab responses after one-time vaccination (Figure 1(b)). The levels of anti-VTT Nabs, however, varied depending on the route of vaccination. Apparently, higher levels of Nabs were induced via the i.n. and i.o. inoculations when compared with the i.m. and s.c. routes. The serum dilution factors based on the IC₅₀ value via the different routes (i.n., i.o., i.m., and s.c.) were 1:711, 1:2370, 1:428, and 1:32, respectively.

3.2. Mucosal Vaccination Also Induced Higher Sustained Levels of Nabs over time. In order to measure the long-lasting levels of Nabs generated, we kept separate groups of the vaccinated animals for six months. Despite the virulent effects of VTT (e.g., body weight changes) during the acute phase of vaccination, all mice survived for continuous observation. After six months of the vaccination, serum samples were collected and subsequently subjected to the same neutralization assay. Interestingly, although the IC₅₀ was not significantly improved for the i.o. group, the rest of three groups of mice, especially the i.n. group, developed higher levels of lasting antivaccinia Nabs when compared to the early time point (Figures 1(b) and 1(c)), suggesting a prolonged VTT-antigen stimulation to immune system. The serum dilution factors based on the IC₅₀ value via the different routes (i.n. and i.o. versus i.m. and s.c.) were 1:2265 and 1:2397 (average 1:2331) versus 1:671 and 1:387 (average 1:529), respectively (Table 1). Furthermore, higher levels of long-lasting antivaccinia Nabs were consistently found in the i.n. and i.o. groups when compared with the i.m. and s.c. groups (Figure 1(c)). The average IC₅₀ value of mucosal groups (i.n. and i.o.) is about 4.4-fold higher than that of i.m. and s.c. routes (1:2331 versus 1:529, P < .01). Randomly selected individual mice of each group were tested with consistent results obtained.

3.3. Protection against Homologous Routes of Mucosal MVTT-S Challenges. To determine the long-lasting efficacy of the four routes of VTT vaccination in parallel, ten groups of vaccinated mice were challenged with MVTT-S six months after the vaccination. Each mouse received 2 × 10⁶ PFU of MVTT-S, the highest possible dose based on our viral stocks, via the i.n. or i.o. routes, respectively, which mimic the natural transmission of the variola virus. Since no anti-S antibodies were detected three weeks after challenge in all groups, we subsequently gave another MVTT-S challenge at the same dose in the same way. We found that i.o. and i.n. VTT vaccinations protected mice significantly against the homologous i.o. and i.n. MVTT-S challenges, respectively, without anti-S antibodies detected after the second challenge (Figure 2(a) and Table 1). The lack of seroconversion to S serves as a biomarker of the protection against MVTT-S infection.

3.4. Protection against Alternating Routes of Mucosal MVTT-S Challenges. We then analyzed other groups of animals. We found that i.o. and i.n. VTT vaccinations protected mice completely against heterologous routes of i.n. and i.o. MVTT-S challenges, respectively, without any detectable anti-S Nabs (Figure 2(a)). In contrast, MVTT-S challenges resulted in high levels of anti-S Nabs in VTT-naïve or nonvaccinated mice after the second challenge (Figure 2(a)). The IC₅₀ values reached over 1:10,000 serum dilution titer. Moreover, i.m. VTT vaccination also protected mice completely against i.n. and i.o. MVTT-S challenges, respectively (Figure 2(a)). Here, the lack of detectable anti-S Nabs after two consecutive MVTT-S challenges likely suggests a possible complete protection (Figure 2(a)). Notably, the s.c. VTT vaccination did not completely protect mice against i.n. or i.o. MVTT-S challenges as anti-S antibodies were readily detected three weeks after the second challenge (Figure 2(b)). Since the mean anti-S IC₅₀ titer of all s.c. vaccinated mice was significantly lower than that of all nonvaccinated controls (1:1778 versus 1:14678, P = .03) (Figures 2(a) and 2(b)), we speculated that at least partial significant protection was achieved by the s.c. VTT vaccination. This P = .03 value was determined by comparing the anti-S mean value of the s.c. vaccinated group (1:1598, 1:1026, and 1:2710, with an average value of 1:1778) versus control group (1:14261, 1:8251, and 1:21523, with an average value of 1:14678). It is possible that the less protection of s.c. vaccinated mice is related to lower levels of anti-VTT neutralizing antibodies induced (Figure 1(a) and Table 1). Since MVTT-S causes transient viremia and infection in mice as we recently described [19], our efforts to detect live challenge virus around three weeks after each challenge in all groups were unsuccessful.

3.5. Lack of Complete Protection against Intramuscular MVTT-S Challenges. Since mucosal VTT vaccination induced likely full protection against homologous and heterologous routes of mucosal MVTT-S challenges (Figure 2(a)), we sought to determine whether the protection would apply to a systemic route of viral challenge. For this
Figure 1: Anti-VTT neutralizing antibody responses after the VTT vaccination. (a) A FACS-based neutralization assay was newly developed to measure the anti-VTT neutralizing antibody responses. (b) Serum samples were tested three weeks after the VTT vaccination. (c) Serum samples were tested six months after the VTT vaccination. Due to a limited amount of serum collected from each mouse, pooled sera, which contain an equal amount of serum of each vaccinated mouse in each group, were subjected to each experiment. The X-axis represents the serum dilution factor whereas the Y-axis indicates the percentage of viral inhibition. An IC_{50} value is a serum dilution factor which achieves 50% of viral inhibition as indicated by the dashed horizontal line. The experiment was repeated twice with similar results obtained. Placebo (no VTT) mice were tested as well.

Table 1: Neutralizing antibody titer from different time points after VTT vaccination and MVTT-S Challenges.

| Groups          | i.m.  | i.n.  | i.o.  | s.c.  | placebo |
|-----------------|-------|-------|-------|-------|---------|
| Vaccination     |       |       |       |       |         |
| VTT (3 weeks)   | NA    | 428   | NA    | 711   | NA      |
| VTT (6 months)  | NA    | 671   | NA    | 2265  | NA      |
| VTT (3 months)  | NA    | 2397  | NA    | 387   | NA      |
| MVTT-S Challenge|       |       |       |       |         |
| i.m. (1st)      | ND    | 3288  | ND    | 5249  | ND      |
| i.m. (2nd)      | 2732  | 6280  | 9369  | 5210  | 936     |
| i.n. (1st)      | ND    | 2065  | ND    | 5141  | ND      |
| i.n. (2nd)      | ND    | 1587  | ND    | 2944  | ND      |
| i.o. (1st)      | ND    | 4555  | ND    | 4937  | ND      |
| i.o. (2nd)      | ND    | 2362  | ND    | 5148  | ND      |

The values of anti-S IC_{50} are in bold whereas the values of anti-VTT IC_{50} are not. NA: not applied; ND: not detected.
Figure 2: Anti-S neutralizing antibody responses in VTT-vaccinated mice after two MVTT-S challenges. (a) Serum samples of i.m., i.n., and i.o. VTT-vaccinated as well as of placebo-inoculated (no VTT) mice were tested. (b) Serum samples of s.c. VTT-vaccinated mice were tested. Pooled sera, which contain an equal amount of serum of each vaccinated mouse in each group, were subjected to each experiment. The X-axis represents the serum dilution factor whereas the Y-axis indicated the percentage of viral inhibition. The dashed horizontal line indicates IC₅₀ values. The experiment was repeated twice with similar results obtained.

Figure 3: Anti-S neutralizing antibody responses in VTT-vaccinated mice after two i.m. MVTT-S challenges. Serum samples collected three weeks after the second MVTT-S challenge were tested in this experiment. Pooled sera, which contain an equal amount of serum of each vaccinated mouse in each group, were subjected to each experiment. The X-axis represents the serum dilution factor whereas the Y-axis indicated the percentage of viral inhibition. The dashed horizontal line indicates IC₅₀ values. The experiment was repeated twice with similar results obtained. As controls, no VTT represents mice, who did not receive VTT-vaccination.
4. Discussion

The smallpox vaccination, which involves live vaccinia virus, remains a gold standard of vaccines because it has led to the complete eradication of a deadly human viral disease. To our knowledge, this study is the first to provide a parallel experimental comparison of four different routes of VTT vaccination for inducing protective efficacy in a mouse model. We provide evidence that one-time vaccination with VTT through each of four different routes was able to induce long-lasting antivaccinia Nabs responses in mice. Apparently, higher levels (4.4-fold) of the Nabs responses were induced via the mucosal i.n. and i.o. inoculations when compared with the i.m. and s.c. routes. Moreover, the i.n. and i.o. VTT vaccination likely protected animals completely from two consecutive mucosal challenges of the MVTT-S strain via either homologous (i.n. and i.o.) or heterologous (i.o. and i.n.) routes, respectively, (Figure 2(a)). As controls, s.c. VTT vaccination did not achieve full protection against i.m., i.n., or i.o. MVTT-S challenges, respectively, (Figure 2(b)). While i.m. VTT vaccination fully protected animals from i.m., i.n., and i.o. MVTT-S challenges, i.m., i.n., and i.o. VTT-vaccinated animals were not fully protected from i.m. challenges (Figures 2(a) and 3). Our results, therefore, suggested that the route of VTT vaccination is critical for inducing protection in mice. In the meantime, the finding that i.m. MVTT-S challenge overcomes preexisting antivaccinia immunity induced via mucosal routes has implications for MVTT-based mucosal vaccine development.

The route of VTT vaccination determines the level of long-lasting antivaccinia Nabs induced. It has been demonstrated that Nabs induced by vaccinia vaccine play an essential role in providing sterile immunity against smallpox infections [25, 26]. Here we show that VTT displays an advantage for inducing higher levels of antivaccinia Nabs comparable levels with IC\textsubscript{50} values of 1:3303, 1:5109, and 1:4727, respectively, which is not statistically significant (Figure 4(a)). This \( P \) value was calculated from the average values of anti-VTT Nabs after the first challenge from three groups: i.m. (1:3288, 1:2065, and 1:4555, with an average of 1:3303), i.n. (1:5249, 1:5141, and 1:4937, with an average of 1:5109), and i.o. (1:4742, 1:6838, 1:2601, with an average of 1:4727). In addition, we determined the anti-VTT Nab response after the second challenge of MVTT-S. We found that the average serum dilution titer of anti-VTT Nabs among i.m., i.n., and i.o. pre-VTT-vaccinated mice had likely saturated at comparable levels with the IC\textsubscript{50} values of 1:3410, 1:4434, and 1:5276, respectively, which is not statistically significant (Figure 4(b)). This \( P \) value was calculated from the average values of anti-VTT Nabs after the second challenge from three groups: i.m. (1:6280, 1:1587, and 1:2362, with an average of 1:3410), i.n. (1:5210, 1:2944, and 1:5148, with an average of 1:4434), and i.o. (1:4721, 1:6205, and 1:4901, with an average of 1:5276). Apparently, these levels of the recalled anti-VTT Nabs were sufficient to block completely the mucosal (i.n. and i.o.) but not the systemic (i.m.) MVTT-S challenges, suggesting a likely difference between mucosal and systemic immunity.
through the noninvasive mucosal route of vaccination. The underlying mechanism of this finding remains largely unknown, although we have recently provided evidence that the tissue tropism may play a role in affecting the immunogenicity of a vaccinia-based vaccine [19]. Since VTT and its variants unlikely establish long-term persistent infection in mice, mechanisms for the maintenance of immunological memory for lasting Nabs remain to be further investigated [8]. One study showed that antigen can be retained in the draining lymph nodes for extended periods of time [27]. Whether this finding would have implications for the continuous maturation of VTT-induced Nabs observed in our study will require future studies. We acknowledge that different route of vaccination may have different protective effects. We did not conduct a direct comparison between intradermal (i.d.) vaccination with other routes because i.d. vaccination did not seem to induce high levels of Nabs in our previous studies [17]. We, however, will compare the skin scarification vaccination with other routes in our future studies as it conferred sterile protection in humans against smallpox infection historically.

Traditional VV challenge models involved the use of highly pathogenic and lethal dose viruses for challenges, which require special biosafety containments. In this study, we developed a convenient model for animal challenge based on testing of the antibody response to the highly immunogenic S protein. Through our protocol, the preparation of vaccinia virus was mostly intracellular mature virion (IMV) particles. Since the S spike protein was not located on the IMV by Western blot analysis (data not shown), the MVTT-S particles themselves cannot induce S-specific antibodies unless they enter the cells and initiate infection. This design provides anti-S antibody as a valuable biological indicator for protection of MVTT-S challenge in mice and eliminates the biosafety issues related to the restricted use of pathogenic vaccinia WR by laboratory regulations [28], as well as helps to reduce study costs. Nonpathogenic viral challenge model has previously been used to study the neutralizing antibody-mediated protection against immunodeficiency viral infection [29]. We, however, recognize the limitation of our experimental system because there might be major differences between lethal and nonpathogenic vaccinia challenge systems. For example, NKT-cells, CD8+ CTLs together with Nabs may be involved in protection against a highly pathogenic virus [30]. This issue should be further studied in future studies.

Mucosal VTT vaccination elicited protection against both homologous and heterologous routes of mucosal MVTT-S challenges. Our results have provided scientific evidence that mucosal VTT vaccination (e.g., one time i.n. or i.o. VTT vaccination in this study) likely confers complete protection against mucosal routes of viral challenges (Figure 2(a)), which is consistent to previous findings [14, 31]. These findings are relevant to smallpox prevention as it conferred sterile protection in humans against smallpox infection historically.

One obstacle of the application of vaccinia-based vaccine is the preexisting antivector immunity [35]. This is often an issue for the clinical development of a vaccinia-based vaccine. Previous studies indicated that mucosal vaccination overcomes preexisting antivaccinia immunity generated through skin vaccination [35, 36]. Consistently, we showed that i.n. or i.o. MVTT-S challenges overcame preexisting antivaccinia immunity generated through s.c. VTT vaccination for inducing anti-S Nabs (Figure 2(b)) [17]. Moreover, we now provide a new finding that i.m. MVTT-S challenges overcome preexisting antivaccinia immunity generated through s.c., i.n., or i.o. route of VTT vaccination (Figures 2(a) and 3). Our findings have implications either for overcoming the preexisting antivaccinia immunity or for improving the immunogenicity of a vaccinia-based vaccine. Since vaccinia-based vaccines have been developed for inducing protective immune responses at the mucosal sites of viral transmission for HIV and other pathogens [37–39], our findings provide evidence to support a new strategy of heterologous routes of prime and boost vaccination using the same vaccine. In comparison to heterologous prime and boost regimens using different viral vectors [40, 41], this is an area of interest for further investigations.

One limitation of our study is the lack of measurements of T-cell-mediated immunity. Besides Nabs, it is possible that the observed VTT-induced protection was partially contributed by cell-mediated immunity. To this end, the mucosal route of vaccination may also be crucial for the generation of highly protective T-cell-mediated immunity. A recent study demonstrated that protection against lethal respiratory vaccinia challenge requires both respiratory mucosal TEM cells and central memory T cells [42]. A future study is, therefore, necessary to address the protective effects of specific cell-mediated immunity under the similar experimental conditions.

**Acknowledgments**

This work was supported by the Chinese 973 project 2006CB504208, the 11th 5-year project 2008ZX10001-011 and 2008ZX10001-015, Hong Kong research grant council...
(HK-RGC762209 to ZC), and the UDF/LKS grants of the University of Hong Kong to its AIDS Institute. We thank Jenny Ng for editorial inputs. B. Lu, W. Yu, and X. Huang contributed equally to this work.

References

[1] V. A. Fulginiti, A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson, “Smallpox vaccination: a review, part II. Adverse events,” *Clinical Infectious Diseases*, vol. 37, no. 2, pp. 251–271, 2003.

[2] S. D. Nafziger, “Smallpox,” *Critical Care Clinics*, vol. 21, no. 4, pp. 739–746, 2005.

[3] D. A. Henderson, “The eradication of smallpox,” *Scientific American*, vol. 235, no. 4, pp. 25–33, 1976.

[4] M. A. Sauri, J. A. Frelinger, M. L. Garba, R. B. Belshe, and S. E. Frey, “Responses to smallpox vaccine,” *The New England Journal of Medicine*, vol. 347, no. 9, pp. 689–690, 2002.

[5] D. L. Heymann, “Smallpox containment updated: considerations for the 21st century,” *International Journal of Infectious Diseases*, vol. 8, supplement 2, pp. S15–S20, 2004.

[6] I. J. Amanna, I. Messaoudi, and M. K. Slikha, “Protective immunity following vaccination: how is it defined?” *Human Vaccines*, vol. 4, no. 4, pp. 316–319, 2008.

[7] I. J. Amanna, N. E. Carlson, and M. K. Slikha, “Duration of humoral immunity to common viral and vaccine antigens,” *The New England Journal of Medicine*, vol. 357, no. 19, pp. 1903–1915, 2007.

[8] I. J. Amanna, M. K. Slikha, and S. Crotty, “Immunity and immunological memory following smallpox vaccination,” *Immunological Reviews*, vol. 211, pp. 320–337, 2006.

[9] S. Mahalingam, I. K. Damon, and B. A. Lidbury, “25 years since the eradication of smallpox: why poxvirus research is still relevant,” *Trends in Immunology*, vol. 25, no. 12, pp. 636–639, 2004.

[10] R. Weltzin, J. Liu, K. V. Pugachev et al., “Clonal vaccinia virus grown in cell culture as a new smallpox vaccine,” *Nature Medicine*, vol. 9, no. 9, pp. 1125–1130, 2003.

[11] X. Tang and Z. Chen, “The development of an AIDS mucosal vaccine,” *Viruses*, vol. 1, no. 2, pp. 283–297, 2010.

[12] F. Fenner, D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi, *Smallpox and Its Eradication*, World Health Organization, Geneva, Switzerland, 1988.

[13] S. L. Dong, Q. C., “The founder of vaccinia virus Tiantan strain,” *Weishengwuxue Mianyixue Jinzhan*, vol. 37, no. 3, pp. 1–3, 2009.

[14] W. Yu, Q. Fang, W. Zhu et al., “One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge,” *Vaccine*, vol. 28, no. 9, pp. 2088–2096, 2010.

[15] M. Kretschmar, J. Wallinga, P. Teunis, S. Xing, and R. Mikolajczyk, “Frequency of adverse events after vaccination with different vaccinia strains,” *PloS Medicine*, vol. 3, no. 8, article e272, 2006.

[16] Q. Fang, L. Yang, W. Zhu et al., “Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain,” *Virology*, vol. 335, no. 2, pp. 242–251, 2005.

[17] X. Huang, B. Lu, W. Yu et al., “A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination,” *PloS One*, vol. 4, no. 1, Article ID e1180, 2009.

[18] D. C. Tcharke, P. C. Reading, and G. L. Smith, “Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes,” *Journal of General Virology*, vol. 83, part 8, pp. 1977–1986, 2002.

[19] H. Liu, W. Yu, X. Tang et al., “The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice,” *Journal of Medical Virology*, vol. 82, no. 5, pp. 727–734, 2010.

[20] X. Huang, L. Liu, L. Ren, C. Qiu, Y. Wan, and J. Xu, “Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses,” *Vaccine*, vol. 25, no. 32, pp. 8874–8884, 2007.

[21] W. K. Joklik, “The purification of four strains of poxvirus,” *Virology*, vol. 18, no. 1, pp. 9–18, 1962.

[22] Z. Chen, L. Zhang, C. Qin et al., “Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region,” *Journal of Virology*, vol. 79, no. 5, pp. 2678–2688, 2005.

[23] C. Tsai, C. Caillet, H. Hu et al., “Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase,” *Vaccine*, vol. 27, no. 48, pp. 6777–6790, 2009.

[24] P. L. Earl, J. L. Americo, and B. Moss, “Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein,” *Journal of Virology*, vol. 77, no. 19, pp. 10684–10688, 2003.

[25] M. R. E. Benhnia, M. M. McCausland, H. P. Su et al., “Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine,” *Journal of Virology*, vol. 82, no. 7, pp. 3751–3768, 2008.

[26] Y. Edghill-Smith, H. Golding, J. Manischewitz et al., “Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus,” *Nature Medicine*, vol. 11, no. 7, pp. 740–747, 2005.

[27] N. Fazilleau, M. D. Eisenbraun, L. Malherbe et al., “Lymphoid reservoirs of antigen-specific memory T helper cells,” *Nature Immunology*, vol. 8, no. 7, pp. 753–761, 2007.

[28] J. M. Neff, L. J. Michael, V. A. Fulginiti, and D. A. Henderson, “Contact vaccinia—transmission of vaccinia from smallpox vaccination,” *Journal of the American Medical Association*, vol. 288, no. 15, pp. 1901–1905, 2002.

[29] H. L. Robinson, D. C. Montefori, R. P. Johnson et al., “Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations,” *Nature Medicine*, vol. 5, no. 5, pp. 526–534, 1999.

[30] J. T. Snyder, I. M. Belyakov, A. Dzutev, F. Lemonnier, and J. A. Berzofsky, “Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses,” *Journal of Virology*, vol. 78, no. 13, pp. 7052–7060, 2004.

[31] W. Kastenmuller, G. Gasteiger, L. Stross, D. H. Busch, and L. Drexler, “Cutting edge: mucosal application of a lophyphilic viral vector vaccine confers systemic and protective immunity toward intracellular pathogens,” *Journal of Immunology*, vol. 182, no. 5, pp. 2573–2577, 2009.

[32] E. Elst, “The transmission mechanism of smallpox,” *Ärztlche Forschung*, vol. 9, no. 1, pp. 13–32, 1955.

[33] I. M. Belyakov, D. Isakov, Q. Zhu, A. Dzutev, D. Klinzman, and J. A. Berzofsky, “Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective
efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host,” *Journal of Immunology*, vol. 177, no. 9, pp. 6336–6343, 2006.

[34] I. M. Belyakov, P. Earl, A. Dzutsev et al., “Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 16, pp. 9458–9463, 2003.

[35] I. M. Belyakov, B. Moss, W. Strober, and J. A. Berzofsky, “Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 8, pp. 4512–4517, 1999.

[36] T. Naito, Y. Kaneko, and D. Kozbor, “Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization,” *Journal of General Virology*, vol. 88, part 1, pp. 61–70, 2007.

[37] C. Ranasinghe, J. C. Medveczky, D. Woltring et al., “Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1,” *Vaccine*, vol. 24, no. 31-32, pp. 5881–5895, 2006.

[38] F. Martinon, P. Brochard, M. Ripaux et al., “Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus,” *Vaccine*, vol. 26, no. 4, pp. 532–545, 2008.

[39] N. P. Goonetilleke, H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. S. Hill, “Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara,” *Journal of Immunology*, vol. 171, no. 3, pp. 1602–1609, 2003.

[40] S. Lu, “Heterologous prime-boost vaccination,” *Current Opinion in Immunology*, vol. 21, no. 3, pp. 346–351, 2009.

[41] L. Ba, C. E. Yi, L. Zhang, D. D. Ho, and Z. Chen, “Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus,” *Applied Microbiology and Biotechnology*, vol. 76, no. 5, pp. 1131–1136, 2007.

[42] L. Liu, Q. Zhong, T. Tian, K. Dubin, S. K. Athale, and T. S. Kupper, “Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity,” *Nature Medicine*, vol. 16, no. 2, pp. 224–227, 2010.